Analyst Price Target is $8.40
▲ +328.57% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Erasca in the last 3 months. The average price target is $8.40, with a high forecast of $11.00 and a low forecast of $6.00. The average price target represents a 328.57% upside from the last price of $1.96.
Current Consensus is
The current consensus among 4 polled investment analysts is to moderate buy stock in Erasca. This Moderate Buy consensus rating has held steady for over two years.
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.